Irbesartan E Idroclorotiazide Tecnigen

Irbesartan, the active ingredient in Irbesartan E Idroclorotiazide Tecnigen, is an Angiotensin II receptor blocker (ARB) presented as a combined tablet for oral use. It is used to treat hypertension, often in patients who benefit from the added diuretic effect of hydrochlorothiazide.

GNH USA supplies Irbesartan E Idroclorotiazide Tecnigen as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Irbesartan/Hydrochlorothiazide acts on the renin‑angiotensin‑aldosterone system and renal sodium handling to control elevated blood pressure. - Hypertension: lowers systolic and diastolic pressure in patients with primary or secondary hypertension. - Resistant hypertension: provides additional blood‑pressure reduction when monotherapy is insufficient. - Hypertensive renal disease: helps control pressure while reducing fluid overload.

Common Side Effects: - Dizziness: mild to moderate light‑headedness, especially after the first dose. - Headache: transient tension‑type headaches. - Fatigue: general tiredness that often improves with continued therapy. - Increased urination: due to the diuretic component. - Electrolyte imbalance: mild reductions in potassium or sodium levels. - Gastrointestinal discomfort: occasional nausea or abdominal cramping.

Serious or Rare Side Effects: - Severe allergic reaction: rash, swelling, or difficulty breathing. - Acute kidney injury: sudden rise in serum creatinine. - Significant hypotension: marked drop in blood pressure causing faintness. - Hyperkalemia: elevated potassium levels, especially when combined with potassium‑sparing agents. - Pancreatitis: rare inflammation of the pancreas. - Liver dysfunction: abnormal liver enzyme elevations.

Before initiating therapy, assess baseline blood pressure, renal function, and electrolyte status. - Monitor blood pressure: adjust dose based on response. - Check renal function: periodic serum creatinine and eGFR measurements. - Assess electrolytes: especially potassium and sodium levels. - Use caution in elderly patients: increased sensitivity to hypotension. - Avoid in severe hepatic impairment: limited data on safety. - Store at below 25°C: keep in the original container, protect from moisture and direct sunlight.

Irbesartan/Hydrochlorothiazide may interact with several medicines that affect blood pressure, renal function, or electrolyte balance. Major Interactions (Avoid): - Potassium‑sparing diuretics: risk of hyperkalemia. - ACE inhibitors or aliskiren: additive renal effects. - NSAIDs: may blunt antihypertensive response and affect kidney function. - Lithium: increased lithium levels and toxicity. - High‑dose potassium supplements: risk of severe hyperkalemia.

Moderate Interactions (Monitor Closely): - Beta‑blockers: may enhance hypotensive effect. - Calcium channel blockers: additive blood‑pressure lowering. - Antidiabetic agents: may require dose adjustment due to improved glycemic control. - Antihistamines: possible increase in diuretic‑related dehydration. - Rifampin: may reduce plasma concentrations of irbesartan.